Stingeni Luca, Ferrucci Silvia, Amerio Paolo, Foti Caterina, Patruno Cataldo, Girolomoni Giampiero
Dermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Dermatology Section, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
Expert Opin Biol Ther. 2025 Jan;25(1):15-20. doi: 10.1080/14712598.2024.2435427. Epub 2024 Dec 6.
Atopic dermatitis (AD) is a common chronic inflammatory skin disease. Moderate-to-severe AD severely affects patients' quality of life. New drugs selectively targeting molecular pathways involved in the pathogenesis of the disease led to a new era for the treatment of AD. However, the current available options are limited and do not completely fulfill patients' needs. Recently, lebrikizumab, a new humanized monoclonal antibody targeting IL-13, has been approved for treating moderate-to-severe AD.
By analyzing scientific literature reporting lebrikizumab phase 3 pivotal clinical studies and summarizing recent advances in AD pathogenesis, in this article we focused on the mechanism of action of lebrikizumab in comparison to other biologics used for treating AD and discussed clinical data that led to the approval of this biologic agent.
Among biologics approved for moderate-to-severe AD, lebrikizumab is characterized by a unique mechanism of action and an attractive maintenance regimen, besides good efficacy and safety profiles. Moreover, clinical evidence suggests that patients naïve or pre-treated with other biologics and affected by AD localized in sensitive areas and by type 2 comorbidities might be successfully treated with lebrikizumab.
特应性皮炎（AD）是一种常见的慢性炎症性皮肤病。中重度AD严重影响患者的生活质量。选择性靶向该疾病发病机制中相关分子途径的新药开启了AD治疗的新时代。然而，目前可用的治疗选择有限，无法完全满足患者的需求。最近，一种靶向IL-13的新型人源化单克隆抗体——lebrikizumab已被批准用于治疗中重度AD。
通过分析报道lebrikizumab 3期关键临床研究的科学文献，并总结AD发病机制的最新进展，在本文中，我们重点关注了lebrikizumab与其他用于治疗AD的生物制剂相比的作用机制，并讨论了导致该生物制剂获批的临床数据。
在获批用于治疗中重度AD的生物制剂中，lebrikizumab除了具有良好的疗效和安全性外，还具有独特的作用机制和有吸引力的维持治疗方案。此外，临床证据表明，初治或曾接受其他生物制剂治疗、患有AD且病变位于敏感部位以及伴有2型合并症的患者，使用lebrikizumab可能会得到成功治疗。
